Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC–MS/MS and its application to a pharmacokinetic study

Jacobson, 2010, Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection, Clin. Gastroenterol. Hepatol., 8, 924, 10.1016/j.cgh.2010.06.032 Poynard, 2010, Perspectives on fibrosis progression in hepatitis C: an a la carte approach to risk factors and staging of fibrosis, Antivir. Ther., 15, 281, 10.3851/IMP1535 Veldt, 2007, Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis, Ann. Intern. Med., 147, 677, 10.7326/0003-4819-147-10-200711200-00003 Bruno, 2010, Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study, Hepatology, 51, 2069, 10.1002/hep.23528 Ng, 2011, Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C, Clin. Gastroenterol. Hepatol., 9, 923, 10.1016/j.cgh.2011.05.028 Vierling, 2014, Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials, J. Hepatol., 61, 200, 10.1016/j.jhep.2014.03.022 Hezode, 2014, Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis, Gastroenterology, 147, 132, 10.1053/j.gastro.2014.03.051 Colombo, 2014, Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: the international telaprevir access program, J. Hepatol., 61, 976, 10.1016/j.jhep.2014.06.005 Hezode, 2013, Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890, J. Hepatol., 59, 434, 10.1016/j.jhep.2013.04.035 Bourliere, 2012, Future treatment of patients with HCV cirrhosis, Liver Int., 32, 113, 10.1111/j.1478-3231.2011.02702.x Afdhal, 2014, Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection, N. Engl. J. Med., 370, 1483, 10.1056/NEJMoa1316366 Lawitz, 2014, Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial, Lancet, 383, 515, 10.1016/S0140-6736(13)62121-2 Kumari, 2015, Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1, Expert Opin. Pharmacother., 16, 739, 10.1517/14656566.2015.1013938 Mizokami, 2015, Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial, Lancet Infect. Dis., 15, 645, 10.1016/S1473-3099(15)70099-X Kohli, 2014, Treatment of hepatitis C: a systematic review, Jama, 312, 631, 10.1001/jama.2014.7085 Afdhal, 2014, Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection, N. Engl. J. Med., 370, 1889, 10.1056/NEJMoa1402454 Kowdley, 2014, Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis, N. Engl. J. Med., 370, 1879, 10.1056/NEJMoa1402355 Rezk, 2015, Development of a sensitive UPLC–ESI–MS/MS method for quantification of sofosbuvir and its metabolite, GS-331007, in human plasma: application to a bioequivalence study, J. Pharm. Biomed. Anal., 114, 97, 10.1016/j.jpba.2015.05.006 de Villiers, 2006, Evaluation of ultra performance liquid chromatography. Part I. Possibilities and limitations, J. Chromatogr. A, 1127, 60, 10.1016/j.chroma.2006.05.071 Qiu, 2014, Simultaneous determination of bosentan and glimepiride in human plasma by ultra performance liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study, J. Pharm. Biomed. Anal., 95, 207, 10.1016/j.jpba.2014.03.011 Qiu, 2014, Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma by ultra high performance liquid chromatography tandem mass spectrometry and its application to a bioequivalence study, J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci., 957, 110, 10.1016/j.jchromb.2014.03.002 (US Food and Drug Administration. Guidance for Industry-Bioanalytical Method Validation. US Department of Health and Human Services, CDER and CVM: Rockville, MD, 2001).